Mindreader Biotech (@MindreaderBio) header
Mindreader Biotech (@MindreaderBio) profile picture

PhD (molecular biology) + MD Bridging Science and the Markets in Biotechnology

New York, NY
Joined October 2025
Photo by Mindreader Biotech (@MindreaderBio)Photo by Mindreader Biotech (@MindreaderBio)Photo by Mindreader Biotech (@MindreaderBio)Photo by Mindreader Biotech (@MindreaderBio)Photo by Mindreader Biotech (@MindreaderBio)Photo by Mindreader Biotech (@MindreaderBio)Photo by Mindreader Biotech (@MindreaderBio)Photo by Mindreader Biotech (@MindreaderBio)Photo by Mindreader Biotech (@MindreaderBio)Photo by Mindreader Biotech (@MindreaderBio)
Checkpoint blockade removes the PD-1 brake on CD8 T cells. But brake release ≠ engine restoration. Exhausted T cells need metabolic support and persistence signals (think IL-15 biology). The Anktiva. The next wave in oncology isn’t stronger chemo. It’s immune system architecture. @DrPatrick @elonmusk @ImmunityBio @Biotech2k1 @_Biotech_iQ #Immunology #Sciencecommunication #Oncology #biotech #CancerResearch $IBRX #StocksInFocus
1
4
3
22
11,075
$SLS congratulations to a guy who took the hits Angelo Stergiou
239
$SMMT as Rome burns FDA fiddles.Another smack of the hand from the FDA.`Our standards are so much higher than the Chinese.’The tension here is we have a drug that most people agree works and would be an improvement. It’s OK for SMMT they have the cash to do another trial but our risk averse FDA helps move the center of gravity to China.Our biotech companies are choking from lack of capital.Ivonescimab should have been approved.FDA needs to wake up.
2
1,130
$NUVB Not sure what it would take to move this stock in the right direction but their update on Phase 2 chemo and radiotherapy naive grade 2 IDH1-mutant glioma is very promising.
3
242
$SMMT getting hammered Top executives at the company not selling a share and own over 81% of the company.Last big buys in June.
1
5
1,286
$ELDN across the board bear market has this company under tremendous stress.Chicago Medicine Transplant Institute uses tegoprubart not tacrolimus for its pancreatic islet graft study with stellar results.Pretty amazing that they would choose this drug over the standard of care.Why ?Because it’s much better and they had great data from the BESTOW trial and these researchers know tacrolimus is renal toxic.Tragic if phase 3 can’t get funded. Drug is being given for compassionate use for transplant patients with renal toxicity on tacrolimus.Time to move on to a superior drug even if it replaces a generic.Better quality of life and non toxic.
1
4
259
$SLS Phase 3 Regal trial results of GPS to be released this month.
326
$SMMT preliminary readouts on critical Phase 3 first line NSCLC squamous sub group PFS due in 4th quarter.
2
434
$CADL disappointed to hear BLA application delayed until 2027 due to assays on commercial product refinement. It’s not like the BLA is postponed for 2 years.From what I can glean there is no change in the Phase 3 data.
1
246
$CLYM keep an eye on this one.Float is 2/3 ‘s in the hands of large institutions.Some positive news coming later in the 4th quarter could make things tight pretty fast.Not much float out there for another large institutional position.
159
Looks like my prediction on global oil prices will come true.Trump administration has certainly refined their approach to Iran.Potentially very potent antidote for inflation.There is more oil around than anyone realizes.Solving Iran crisis pushes oil under $60.
100
$CAPR sounds like a replay of the $REPL fiasco.CDER as discussed by Dr Richard Pazdur is not up to date. It is not possible for them to be making the decisions they’re making without more specialty representation on CDER.They maintained an unreasonable amount of skepticism about RP1 showing shrinkage of non injected lesions and yet if they new the field well they would realize that other researchers were reporting the same phenomenon. Now we have the American Heart Association giving CAPR an outstanding pediatric research award and the FDA saying the drug doesn’t work. With the recent changes at the FDA my opinion on the chance of passage has gone up substantially.Passage of this drug ,just like the passage of $INO new plasmid DNA product is a big boost for US biotech.
1
4
1,209
$BDTX meeting with FDA on plans for Phase 3 silevertinib trial.Promising Phase 2 results.Adequate cash to fund to latter half 2028.
2
350
$BEAM BEACON phase1/2 trial positive.Plans to file a BLA for sickle cell perhaps as early as 2026.
1
2
381
$ALLO interesting allogenic CAR T phase 1 RESOLUTION study of ALLO-329 in 18 autoimmune patients. Results at ACR today. One group had no conditioning lymphocyte depletion.Generally well tolerated and results promising .
4
500
$CMPX still working on BLA for tovecimig for BTC.Confounded results with crossover and the FDA advice. Do another study.These patients could use this drug now and do the study.
184
$ELTX spoke at SITC about their subgroup ctDNA negative group which showed a strong response in AMPLIFY-7P phase 2 trial.Think they very well could get the financing for a phase 3 trial.
2
410
Replying to @biotech_hunter
You must have been at SITC LOL.Interesting presentation
1
77
$CGON a name not to be forgotten.Could be a major competitor in bladder cancer soon.Pretty expensive and with a lot of support and a billion in cash.Had the wrong symbol listed.
2
360